Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KitazatoTSE:368A +0.79%22 Return-on-Tangible-Equity is 21.55% as of Mar. 2026, which is 7% below its 10-year median of 23.12. GuruFocus rates TSE:368A with a GF Score™ of 22/100. Among 758 Medical Devices & Instruments companies, Kitazato ranks better than 83.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kitazato's annualized net income for the quarter that ended in Mar. 2026 was 円4,182 Mil. Kitazato's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円19,411 Mil. Therefore, Kitazato's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.55%.
The historical rank and industry rank for Kitazato's Return-on-Tangible-Equity or its related term are showing as below:
TSE:368A'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 20.16 Med: 23.12 Max: 26.49
Current: 20.5
During the past 4 years, Kitazato's highest Return-on-Tangible-Equity was 26.49%. The lowest was 20.16%. And the median was 23.12%.
TSE:368A's Return-on-Tangible-Equity is ranked better than 83.91% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs TSE:368A: 20.50
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Kitazato Return-on-Tangible-Equity Related Terms
Kitazato Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Kitazato's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:368A vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Kitazato's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kitazato Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kitazato's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kitazato's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.55% mean?
Kitazato (TSE:368A) has a Return-on-Tangible-Equity of 21.55% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kitazato and its competitors. This is near median its historical median of 23.12. Over the past decade, Kitazato's Return-on-Tangible-Equity has ranged from 20.16 to 26.49. According to the industry distribution chart, Kitazato ranks #122 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 16.1%.
Is Kitazato's Return-on-Tangible-Equity too high?
Kitazato's current Return-on-Tangible-Equity of 21.55% is near median its 10-year median of 23.12. Over the past 10 years, this metric has ranged from a low of 20.16 to a high of 26.49. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Kitazato's value of 21.55% is 431.4% above this industry median. Based on the distribution chart, Kitazato ranks #122 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kitazato has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Kitazato's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kitazato ranks #122 out of 758 companies for Return-on-Tangible-Equity. This places Kitazato in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.06. Kitazato's value of 21.55% is 431.4% above this benchmark. Historically, Kitazato's own Return-on-Tangible-Equity has ranged from 20.16 to 26.49 over the past decade. While the company's 10-year median is 23.12 vs. the industry median of 4.06, Kitazato has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kitazato's current Return-on-Tangible-Equity of 21.55% is 431.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kitazato and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kitazato's current Return-on-Tangible-Equity is 21.55%, which is near median its own 10-year median of 23.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kitazato stock overvalued right now?
Kitazato (TSE:368A) has a current Return-on-Tangible-Equity of 21.55%. The current Return-on-Tangible-Equity is 21.55%, which is near median its 10-year median of 23.12 and 431.4% above the Medical Devices & Instruments industry median of 4.06. Kitazato's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Kitazato (TSE:368A), the current Return-on-Tangible-Equity is 21.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kitazato Corp is engaged in manufacture and sale of medical devices and related products for fertility treatment. Its products include Needles, Catheters and Cannulas, Vitrification Media and Equipments, Sperm Processing Medium/Tools, IVF Medium, etc.
22GF Score
Get the complete analysis for TSE:368A
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:368A has been successfully added to your 
